Payment overview · 2025
General Payments
$739.67
40 reported records · 12 companies
Healthcare provider profile · identity verified
Michael E Dant, MD
Allopathic & Osteopathic Physicians|Family Medicine · RINGGOLD, GA · NPI 1518944081
Verified facts
What the public records show
CMS Open Payments records show Michael E Dant, MD received $739.67 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.98 | 22.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.28 | 12.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.50 | 12.0% | 5 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $78.45 | 10.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.78 | 10.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.12 | 8.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $56.75 | 7.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.95 | 6.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.68 | 4.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.57 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.14 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.47 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $739.67 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $153.22 | 10 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $88.50 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $88.50 | 5 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $78.45 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.12 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.29 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $56.75 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.52 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.95 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $9.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $9.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 185 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
53 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
185 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1017 | 259 |
| Levothyroxine Sodium | Levothyroxine Sodium | 637 | 159 |
| Lisinopril | Lisinopril | 576 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 501 | 142 |
| Gabapentin | Gabapentin | 472 | 105 |
| Losartan Potassium | Losartan Potassium | 425 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 402 | 109 |
| Omeprazole | Omeprazole | 396 | 104 |
| Metformin Hcl | Metformin Hcl | 334 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 322 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 69 |
| Potassium Chloride | Potassium Chloride | 236 | 63 |
| Montelukast Sodium | Montelukast Sodium | 227 | 64 |
| Carvedilol | Carvedilol | 220 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 91 |
| Sertraline Hcl | Sertraline Hcl | 210 | 55 |
| Meloxicam | Meloxicam | 208 | 48 |
| Furosemide | Furosemide | 200 | 54 |
| Simvastatin | Simvastatin | 194 | 57 |
| Eliquis | Apixaban | 185 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 174 | 47 |
| Glimepiride | Glimepiride | 163 | 43 |
| Trazodone Hcl | Trazodone Hcl | 160 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 149 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 145 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 45 |
| Clonazepam | Clonazepam | 134 | 25 |
| Mirtazapine | Mirtazapine | 132 | 31 |
| Metformin Hcl Er | Metformin Hcl | 128 | 32 |
| Alprazolam | Alprazolam | 126 | 21 |
| Famotidine | Famotidine | 122 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 26 |
| Buspirone Hcl | Buspirone Hcl | 116 | 22 |
| Ezetimibe | Ezetimibe | 111 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 101 | 26 |
| Finasteride | Finasteride | 100 | 24 |
| Clonidine Hcl | Clonidine Hcl | 98 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 97 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 95 | 21 |
| Promethazine Hcl | Promethazine Hcl | 94 | 23 |
| Celecoxib | Celecoxib | 91 | 21 |
| Estradiol | Estradiol | 90 | 19 |
| Allopurinol | Allopurinol | 89 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 88 | 23 |
| Lorazepam | Lorazepam | 87 | 24 |
| Aripiprazole | Aripiprazole | 84 | 18 |
| Prednisone | Prednisone | 80 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 20 |
| Januvia | Sitagliptin Phosphate | 73 | 17 |
| Ozempic | Semaglutide | 73 | 15 |
| Spironolactone | Spironolactone | 68 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 50 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 15 |
| Donepezil Hcl | Donepezil Hcl | 63 | 15 |
| Pregabalin | Pregabalin | 63 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 18 |
| Meclizine Hcl | Meclizine Hcl | 60 | 30 |
| Ondansetron Odt | Ondansetron | 60 | 20 |
| Azithromycin | Azithromycin | 59 | 43 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 13 |
| Synthroid | Levothyroxine Sodium | 59 | 15 |
| Nabumetone | Nabumetone | 58 | suppressed |
| Atenolol | Atenolol | 57 | 17 |
| Amoxicillin | Amoxicillin | 56 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 11 |
| Naproxen | Naproxen | 53 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 12 |
| Memantine Hcl | Memantine Hcl | 50 | 12 |
| Alendronate Sodium | Alendronate Sodium | 49 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Diazepam | Diazepam | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 36 |
| Sucralfate | Sucralfate | 47 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 12 |
| Valsartan | Valsartan | 45 | 15 |
| Gemfibrozil | Gemfibrozil | 44 | suppressed |
| Premarin | Estrogens, Conjugated | 44 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 38 |
| Tramadol Hcl | Tramadol Hcl | 43 | 14 |
| Lovastatin | Lovastatin | 42 | 12 |
| Terazosin Hcl | Terazosin Hcl | 42 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 11 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Nystatin | Nystatin | 39 | 22 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Cefdinir | Cefdinir | 36 | 29 |
| Linzess | Linaclotide | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Baclofen | Baclofen | 29 | 13 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 13 |
| Fosinopril Sodium | Fosinopril Sodium | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 21 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 11 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | 12 |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Progesterone | Progesterone, Micronized | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 11 |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Famciclovir | Famciclovir | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clarithromycin | Clarithromycin | 12 | 12 |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $739.67 · 40 records | ABBVIE INC. | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FFRct, FREESTYLE LIBRE 3, INCEPTIV, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error